American Heart Journal
Volume 155, Issue 6 , Pages 1081-1089 , June 2008

Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention

  • Giuseppe G.L. Biondi-Zoccai, MD

      Affiliations

    • Division of Cardiology, University of Turin, Turin, Italy
    • Corresponding Author InformationReprint requests: Giuseppe Biondi-Zoccai, MD, Interventional Cardiology, Division of Cardiology, University of Turin, S. Giovanni Battista “Molinette” Hospital, Corso Bramante 88-90, 10126 Turin, Italy.
    • Dr Biondi-Zoccai has consulted for Boston Scientific (Genoa, Italy), Cordis (Milan, Italy), Invatec, and Mediolanum Cardio Research (Milan, Italy), and has received lecture fees from Bristol Myers Squibb (Rome, Italy). This work is part of a senior investigator project for the Meta-analysis and Evidence-based Medicine Training in Cardiology (METCARDIO) Group, based in Turin, Italy (Protocol #4-2007 at http://www.metcardio.org/protocols.html).
    • Both authors equally contributed to this work.
    • ,
  • Marzia Lotrionte, MD

      Affiliations

    • Institute of Cardiology, Catholic University, Rome, Italy
    • Both authors equally contributed to this work.
    • ,
  • Matteo Anselmino, MD

      Affiliations

    • Division of Cardiology, University of Turin, Turin, Italy
    • ,
  • Claudio Moretti, MD

      Affiliations

    • Division of Cardiology, University of Turin, Turin, Italy
    • ,
  • Pierfrancesco Agostoni, MD

      Affiliations

    • Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium
    • ,
  • Luca Testa, MD

      Affiliations

    • Institute of Cardiology, Catholic University, Rome, Italy
    • ,
  • Antonio Abbate, MD

      Affiliations

    • Virginia Commonwealth University Pauley Heart Center, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA
    • ,
  • John Cosgrave, MD

      Affiliations

    • Midland Regional Hospital Mullingar, Mullingar, Ireland
    • ,
  • Antonio Laudito, MD

      Affiliations

    • Division of Cardiac Surgery, University of Turin, Turin, Italy
    • ,
  • Gian Paolo Trevi, MD

      Affiliations

    • Division of Cardiology, University of Turin, Turin, Italy
    • ,
  • Imad Sheiban, MD

      Affiliations

    • Division of Cardiology, University of Turin, Turin, Italy

Received 12 September 2007 ,Accepted 26 December 2007.

References 

  1. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent–controlled trials. Int J Cardiol. 2005;100:119–123
  2. Biondi-Zoccai G, Agostoni P, Moretti C, et al. Making reason of the recent meta-analytic confusion on the safety of drug-eluting stents. EuroInterv. 2007;3:381–385
  3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  4. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  5. Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis. Diabetes Care. 2007;30:384–388
  6. Douglas JS, Holmes DR, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112:2826–2832
  7. El-Beyrouty C, Spinler SA. Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. Ann Pharmacother. 2001;35:1108–1113
  8. Schleinitz MD, Olkin I, Heidenreich PA. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J. 2004;148:990–997
  9. Hashiguchi M, Ohno K, Nakazawa R, et al. Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther. 2004;18:211–217
  10. Agostoni P, Valgimigli M, Abbate A, et al. Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries?. Am J Cardiol. 2006;97:603–605
  11. The Cochrane Collaboration Handbook for Systematic Reviews of Interventions. Available at: http://www.cochrane.org/resources/handbook/Handbook4.2.6Sep2006.pdf(last accessed on 10 August 2007)
  12. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  13. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–680
  14. Kunishima T, Musha H, Eto F, et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 1997;19:1058–1066
  15. Take S, Matsutani M, Ueda H, et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097–1099
  16. Sekiya M, Funada J, Watanabe K, et al. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998;82:144–147
  17. Tsuchikane E, Katoh O, Sumitsuji S, et al. Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am Heart J. 1998;135:495–502
  18. Yamasaki M, Hara K, Ikari Y, et al. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn. 1998;44:387–391
  19. Ochiai M, Isshiki T, Takeshita S, et al. Use of cilostazol, a novel antiplatelet agent, in a post–Palmaz-Schatz stenting regimen. Am J Cardiol. 1997;79:1471–1474
  20. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86:499–503
  21. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21–26
  22. Yoon Y, Shim WH, Lee DH, et al. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol. 1999;84:1375–1380
  23. Kozuma K, Hara K, Yamasaki M, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 2001;141:124–130
  24. Nagaoka N, Matsubara T, Okazaki K, et al. Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J. 2001;42:43–54
  25. Abe Y, Midorikawa H, Muroi S, et al. Multidrug hybrid therapy including an angiotensin receptor antagonist to prevent restenosis after coronary stenting (preliminary report). Jpn J Interv Cardiol. 2002;17:259–262
  26. Kamishirado H, Inoue T, Mizoguchi K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 2002;144:303–308
  27. Mizoguchi K. Prevention study for thrombosis and restenosis occurring after coronary stent implantation: a randomized comparison of cilostazol vs. ticlopidine. Dokkyo J Med Sci. 2003;30:45–52
  28. Inoue T, Uchida T, Sakuma M, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol. 2004;44:1408–1414
  29. Sekiguchi M, Hoshizaki H, Adachi H, et al. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. Circ J. 2004;68:610–614
  30. Ge J, Han Y, Jiang H, et al. RACTS (Randomized Prospective Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting) Trial Investigators. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol. 2005;46:162–166
  31. Han YL, Wang SL, Li Y, et al. Effects of cilostazol on long-term clinical outcomes after coronary stenting. Zhonghua Nei Ke Za Zhi. 2005;44:814–817
  32. Lee SW, Park SW, Hong MK, et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol. 2005;95:859–862
  33. Takeyasu N, Watanabe S, Noguchi Y, et al. Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Circ J. 2005;69:780–785
  34. Chen YD, Lu YL, Jin ZN, et al. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl). 2006;119:360–366
  35. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100:1103–1108
  36. Sorkin EM, Markham A. Cilostazol. Drugs Aging. 1999;14:63–71
  37. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314–1319
  38. Lee BK, Lee SW, Park SW, et al. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and p-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol. 2007;100:610–614
  39. Kubota Y, Kichikawa K, Uchida H. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: an experimental study. Invest Radiol. 1995;30:532–537
  40. Agostoni P, Cosgrave J, Biondi-Zoccai GG, et al. Angiographic analysis of pattern of late luminal loss in sirolimus- and paclitaxel-eluting stents. Am J Cardiol. 2007;99:593–598

PII: S0002-8703(08)00003-3

doi: 10.1016/j.ahj.2007.12.024

American Heart Journal
Volume 155, Issue 6 , Pages 1081-1089 , June 2008

Article Tools

* Image Usage & Resolution